BRAF and cancer: Although BRAF inhibitors are efficient in decreasing cell proliferation via the inhibition of the MAPK/ERK pathway, reactivation of this pathway occurs in 80% of BRAF-inhibitor-resistant cancer cells, suggesting that these cells rapidly adapt to MAPK inhibition [7].